Moderna (MRNA) announced on Tuesday that European regulators have approved the biotechnology company’s right to apply early for approval of its COVID-19 vaccine. As a result, the company’s stock rose in the morning stock market trades 1.3%, which brought each stock to a price of 79.29
MRNA Chief Executive Stéphane...